Cancer Research SABCS Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.
Right arrow Articles by Singh, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.
Right arrow Articles by Singh, R. K.
[Cancer Research 65, 9004-9011, October 1, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Down-Regulation of Vascular Endothelial Cell Growth Factor-C Expression Using Small Interfering RNA Vectors in Mammary Tumors Inhibits Tumor Lymphangiogenesis and Spontaneous Metastasis and Enhances Survival

Zhengtang Chen1,3, Michelle L. Varney1, Matthew W. Backora1, Kenneth Cowan2, Joyce C. Solheim2, James E. Talmadge1 and Rakesh K. Singh1

1 Department of Pathology and Microbiology and 2 Epley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska; and 3 Cancer Center of People's Liberation Army, Xin Qiao Hospital, Third Military Medical University, Chongqing, PR China

Requests for reprints: Rakesh K. Singh, Department of Pathology and Microbiology, 985845 Nebraska Medical Center, Omaha, NE 68198-5845. Phone: 402-559-9949; Fax: 402-559-5551; E-mail: rsingh{at}unmc.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Tumor production of vascular endothelial cell growth factor (VEGF)-C is associated with tumor lymphangiogenesis and lymph node metastasis. In this study, we examined the effects of small interfering RNA (siRNA)–mediated inhibition of VEGF-C on murine mammary tumor growth, metastasis, and survival. The mRNA and protein expression of VEGF-C in murine mammary tumor cells stably transfected with a VEGF-C siRNA vector were significantly lower compared with VEGF-C-control vector-transfected cells. Cl66-siVEGFC tumors had lower levels of lymphangiogenesis and lymph node and spontaneous lung metastasis than Cl66-control tumors. However, we did not observe significant differences in primary tumor growth and experimental lung metastasis between mice injected with Cl66-siVEGFC and Cl66-control cells. In addition, mice bearing Cl66-siVEGFC tumors lived significantly longer than mice bearing Cl66-control tumors. Furthermore, our data suggest that inhibition of VEGF-C modulates immune cell infiltration and their function, which might be critical in tumor immunity. In summary, our data show that inhibition of VEGF-C expression using siRNA-mediated gene silencing vectors reduces lymphangiogenesis and lymph node and spontaneous lung metastasis, and enhances survival.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
At the time of diagnosis, the majority of breast cancer patients have developed lymph node metastases, which function as an important prognostic indicator. Recent studies in animal models suggest that lymphangiogenesis can promote metastasis (1–4). Series of lymphangiogenic factors, such as vascular endothelial growth factor (VEGF)-C and VEGF-D (5–7), and lymphatic markers, such as lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1; refs. 8–13), VEGF receptor 3 (VEGFR-3; ref. 14), podoplanin (15–17), and prox-1 (3, 18, 19), have been identified. The VEGF-C protein belongs to the platelet-derived growth factor family (20) and is a known ligand for VEGFR-3 (Flt4; refs. 21, 22). VEGF-C–dependent activation of VEGFR-3 stimulates growth of lymph endothelial cells and lymphatics (21, 22).

The levels of VEGF-C in primary tumors have significantly correlated with lymph node metastasis in a variety of cancers, including thyroid, prostate, gastric, colorectal, lung, and breast cancer (23–33). Overexpression of VEGF-C in breast cancer cells can potentially increase intratumoral lymphangiogenesis, resulting in significantly enhanced metastasis to regional lymph nodes (4, 7, 34, 35). Despite the continuing accumulation of correlative data, a functional role of VEGF-C in tumor lymphangiogenesis and regional and distant metastasis remain unclear. In the present study, we examined whether inhibition of VEGF-C by gene silencing using mammalian expression vectors expressing small interfering RNA (siRNA) might lead to inhibition of lymphangiogenesis and eventual metastases. We examined the effects of these siRNA-vectors on the inhibition of VEGF-C expression, lymphangiogenesis, primary tumor growth, experimental and spontaneous metastasis, and host survival using a murine mammary tumor model. Our data show that the inhibition of constitutive VEGF-C expression in murine mammary tumors reduces lymphangiogenesis and spontaneous metastasis and increases survival.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice and mammary tumor cells. Female BALB/c mice (6-8 weeks old) were purchased from The Jackson Laboratory (Bar Harbor, ME). Animals were housed in facilities approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the U.S. Department of Agriculture, Department of Health and Human Services, and NIH. The murine mammary tumor cell line Cl66 was propagated and maintained in culture as an adherent monolayer in MEM supplemented with 5% fetal bovine serum (FBS; Life Technologies, Inc., Gaithersburg, MD), 2 mmol/L L-glutamine, sodium pyruvate, nonessential amino acids, vitamin solution, and gentamicin (Mediatech, Herndon, VA). The cells were maintained at 37°C with 5% CO2.

Construction of small interfering RNA expression vectors. We used the pSuppressorNeo siRNA plasmid vector-based GeneSilencer system (Imgenex Corp., San Diego, CA), in which siRNA expression is driven by the U6 RNA promoter, to produce siRNA following stable transfection and selection. We generated two different siRNA vectors. The oligonucleotides 5'-TCGATTACAGTGCCTCTCTCACAAGGAGTACTGCTTGTGAGAGAGGCACTGTAATTTTT-3' and 3'-CTAGAAAAATTACAGTGCCTCTCTCACAAGCAGTACTCCTTGTGAGAGAGGCACTGTAA-5' were used to generate anti–VEGF-C siRNA vector, and oligonucleotides 5'-TCGATCAGTCACTTAATGGTCGTTTTCAAGAGAAACGACCATTAACGTGACTGATTTTT-3' and 3'-AGTCAGTGAATTACCAGCAAAAGTTCTCTTTGCTGGTAATTGCACTGACTAAAAAGATC-5' were used to generate a control siRNA vector. Each oligonucleotide pair (100 pmol) was annealed by incubation at 95°C for 5 minutes and slow cooling. One microliter of this mixture was then ligated into XhoI and XbaI sites on the pSuppressorNeo vector. As a result, two vectors, psi–VEGF-C and psi-control, were generated.

Transfection of murine mammary tumor cells. Cl66 murine mammary tumor cells were transfected with 2 µg DNA using LipofectAMINE Plus reagent (Invitrogen, Carlsbad, CA) according to the protocol of the manufacturer. Transfected Cl66 cells were selected with 400 µg/mL G418-sulfate. Stably transfected Cl66-siVEGFC and Cl66-control cells were obtained and routinely maintained in selection media containing 250 µg/mL of G418-sulfate to avoid overgrowth of nontransfected cells.

Messenger RNA analysis. Total cellular RNA was isolated from Cl66-control or Cl66-siVEGFC cells and murine mammary tumors using Trizol reagent (Invitrogen) and cDNA was synthesized using total RNA (5 µg), oligo(dT)18 primer, and Superscript RT (Invitrogen). Quantitative real-time PCR (qRT-PCR) was done using 2 µL of a 1:100 dilution of first-strand cDNA in FastStart DNA Master SYBR Green I with specific primers and iCycler (Bio-Rad, Hercules, CA). Primers used were as follows: VEGF-C, 5'-CTACAGATGTGGGGGTTGCT-3' and 5'-GCTGCCTGACACTGTGGTAA-3'; glyceraldehyde 3-phosphate dehydrogenase (GAPDH); 5'-AGCCTCGTCCCGTAGACAAAA-3'and 5'-GATGACAAGCTTCCCATTCTCG-3'; LYVE1, 5'-AGACACTTAGCCTGGCGGTA-3' and 5'-GCCCACACTCCGCTATACAT-3'; VEGFR-3, 5'-CCCAGCCATGTACAGAAGGT-3' and 5'-GGCTGGAGTCAGAGGAGTTG-3'; VEGF-A, 5'-TTACTGCTGTACCTCCACC-3' and 5'-ACAGGACGGCTTGAAGATG-3'. The fluorescence intensity of the double-stranded specific SYBR Green I, reflecting the amount of PCR product, was monitored at the end of each cycle. The PCR efficiency was examined by serially diluting the template cDNA and the melting curve data were collected to check the PCR specificity. Each cDNA sample was run triplicate and the corresponding no cDNA sample was included as a negative control. he mRNA levels of each gene were normalized to that of the GAPDH mRNA (36).

In vitro proliferation assay. Cl66-control or Cl66-siVEGFC cells (5 x 103) were seeded into 38 mm2 wells of 96-well flat-bottomed plates in triplicate and allowed to adhere overnight. The cultures were then washed and refed with medium containing different concentrations of FBS (0%, 1.25%, 2.5%, and 5.0%). Following 24, 48, and 72 hours of culture, proliferative activity was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using a microtiter plate reader (Bio-Tek Instruments, Inc., Winooski, VT) at 570 nm. Growth stimulation or inhibition was calculated as (%) = [(A / B) – 1 x 100], where A is the absorbance of treated cells and B is the absorbance of untreated control cells.

Tumorigenicity, metastasis, and survival assays. Cl66-siVEGFC and Cl66-control cells were harvested with 0.25% trypsin and 0.02% EDTA. Trypsinization was stopped with medium containing 10% FBS and cells were washed once and resuspended in HBSS for injection. Only single-cell suspensions with >90% viability (tested by trypan blue exclusion) were used for injections. Cl66-control or Cl66-si-VEGFC cells (1 x 105 cells) in 0.1 mL HBSS were injected into mammary fat pads of female BALB/c mice (20 mice per group). Tumors were measured with calipers twice a week. Tumor volume was calculated by the following formula: volume = W2 x L / 2, where W = short diameter and L = long diameter.

Ten mice per group were sacrificed 6 weeks following tumor cell injection and mammary tumors were harvested. Mice were necropsied for examination of regional lymph node and distant metastases. Mammary tumors, lymph nodes, livers, lungs, and femurs were processed for immunohistochemical analysis (of micrometastasis and lymphangiogenesis) and for Western blot and mRNA analysis (of VEGF-C expression). The remaining 10 mice from each group were monitored for survival studies.

To examine experimental lung metastasis, Cl66-control or Cl66-siVEGFC cells (1 x 105 cells/0.1 mL HBSS/animal) were injected i.v. into female BALB/c mice (20 mice per group). Ten mice from each group were killed 3 weeks following tumor cell injection and their lungs were harvested and fixed in Bouin's solution and scored under a dissecting microscope for the number of metastatic nodules on the lung surface. The remaining 10 mice from each group were monitored for survival studies.

Immunohistochemical analysis. Cl66-control or Cl66-siVEGFC cells cultured in chamber slides were fixed with a cold solution of methanol/acetone (50:50) for 10 minutes. The tumors from Cl66-control– or Cl66-siVEGFC–injected mice were put into optimal cutting temperature compound (Sakura, Tokyo, Japan), and 6 to 8 µm thick sections were cut. VEGF-C, VEGFR-3 (for lymphangiogenesis), and CD31 (for angiogenesis) positivity was analyzed by immunohistochemical techniques. Anti–pan-cytokeratin antibody (Serotec, Inc., Raleigh, NC) was used to determine lymph node metastasis. Briefly, tissue sections were processed for immunohistochemistry using rabbit anti–VEGF-C or goat anti-mouse VEGFR-3 (Flt4) or anti-CD31 or anti–pan-cytokeratin antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, and Serotec). Immunoreactivity was detected using the ABC Elite kit and 3,3'-diaminobenzidine substrate kits (Vector Laboratories, Burlingame, CA) per instructions of the manufacturer. A reddish brown precipitate in the cytoplasm indicated a positive reaction. Negative controls had all reagents included except the primary antibody. The number of positive cells was counted at x400 magnification in area of highest intensity. Each section was examined by two independent observers.

Analysis of tumor-infiltrating leukocytes. T cells and dendritic cell accumulation in Cl66-control and Cl6-siVEGFC tumors was examined by flow cytometry using anti-CD4 (clone H129.19), anti-CD8a (clone 53-6.7), and anti-CD11c (clone HL3) antibodies purchased from BD PharMingen. Tumors were measured; excised, and nonnecrotic tumor tissue was minced. The tumor samples were transferred to 15 mL tube, pelleted by centrifugation at 300 x g, and washed twice in sterile HBSS. The samples were then resuspended in freshly prepared HBSS containing collagenase (200 units/mL) and DNase I (270 Ku/mL) and incubated at 37°C with continuation agitation. Following collagenase dissociation, the cells were passed through 70 µm nylon cell strainer, washed once in HBSS, and layered over Lympholyte-M (Cadarlane, Hornby, Ontario, Canada). After centrifugation, mononuclear cells were collected from interface, washed, and adjusted to a concentration of 1 x 107 cells/mL in 2% FBS/0.1% sodium azide/PBS. Cells (0.1 mL/aliquot) were distributed into 96-well U-bottomed plate and nonspecific binding blocked with 1.5% normal murine serum in 0.1% sodium azide/PBS. Next, samples were stained with primary antibodies labeled with FITC, biotin, or phycoerythrin. Biotinylated antibodies were revealed with allophycocyanin-streptavidin (Molecular Probes, Eugene, OR). Data on the stained samples were acquired with a FACSCalibur flow cytometer (BD ImmunoCytometry System, San Jose, CA). Cell populations were gated on forward and side scatter before analysis of antibody staining. Between 30,000 and 100,000 events were collected per sample and the data were analyzed with Attractors or Cell Quest software (BD ImmunoCytometry System).

Lymphocyte proliferation. Splenocytes from Cl66-control and Cl66-siVEGFC tumor-bearing mice were plated at 0.2 x 106 cell/well and cultured with different concentrations of concanavalin A for 5 days. [3H]Thymidine was added at 1 Ci/well 18 hours before cell harvest. [3H]Thymidine incorporation was quantified by scintillation counting as cpm. Splenocytes from normal nontumor-bearing mice was used as control.

Western blot analysis. Cl66-control or Cl66-siVEGFC cells were seeded in 100 x 20 mm culture dishes. After 48 hours of incubation, cells were washed four times with cold PBS and lysed in M-PER reagent (Pierce Chemicals, Rockford, IL) supplemented with protease inhibitors (15 µmol/L phenylmethylsulfonyl fluoride, 0.5 µg/mL leupeptin, and 0.7 µg/mL pepstain). The mammary tumors from Cl66-control or Cl66-si-VEGFC cells were lysed in T-PER reagent (Pierce Chemicals) supplemented with protease inhibitors. Cellular debris was removed by centrifugation and the proteins (20 µg/lane) were separated on SDS-PAGE and electrotransferred to 0.45 µm nitrocellulose membranes blocked with 5% nonfat dry milk in Triton X-100 containing TBS. Western blot analysis was done with anti–VEGF-C (1:500; Santa Cruz Biotechnology) as the primary antibody. After extensive washing, the membranes were incubated with anti-rabbit antibody conjugated with horseradish peroxidase (Amersham, Piscataway, NJ) at a 1:2,000 dilution for 1 hour and then incubated with avidin-AP (1:10,000) for 30 minutes at room temperature. The membranes were developed by an enhanced chemiluminescence technique using the ECL kit (Amersham) and scanned by a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA). After the scan, the membranes were stripped and reprobed with rabbit anti–{alpha}-actin (1:1,000; Sigma Chemical Co. St. Louis, MO) for determining the relative amounts of protein loaded.

Statistical analysis. The significance of the data was determined by the Student's t test (two-tailed) for all in vitro studies and the Mann-Whitney U-test for in vivo studies. Survival rates were graphed using the Kaplan-Meier method and compared among different groups by log-rank statistical analysis. P < 0.05 was deemed significant. All statistical analyses were done using SPSS software (SPSS, Inc, Chicago IL).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Inhibition of the VEGF-C expression in vitro and in vivo by stable expression of small interfering RNA in murine mammary tumor cells. We constructed a mammalian expression vector to express VEGF-C siRNA constitutively to inhibit endogenous VEGF-C expression. We stably transfected Cl66 murine mammary tumor cells, which express high levels of VEGF-C, with psi–VEGF-C (to generate Cl66-siVEGFC cells) and psi-control (to generate Cl66-control cells). We examined mRNA expression of VEGF-C and VEGF-A, a closely related member of the VEGF family, in these transfected cells to show the specificity of VEGF-C gene silencing. We observed significant inhibition of VEGF-C mRNA expression in Cl66-siVEGFC cells compared with Cl66-control cells (Fig. 1A). We did not observe any difference in the mRNA expression of VEGF-A in Cl66-siVEGFC and Cl66-control cells (Fig. 1B). In addition, Western blot and immunohistochemical analyses showed that Cl66-siVEGFC cells had a significant decrease in VEGF-C protein levels compared with Cl66-control cells (Fig. 1C and D). Further, there was no significant difference in the rate of cell proliferation between Cl66-siVEGFC and Cl66-control cells (data not shown).



View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Inhibition of VEGF-C production in Cl66 cells using a VEGF-C siRNA-expressing mammalian expression vector. The levels of VEGF-C in Cl66 cells stably transfected with control or VEGF-C-siRNA vector were examined for mRNA and protein expression using qRT-PCR, Western blot, and immunohistochemistry. A, expression of VEGF-C–specific mRNA transcript analyzed by qRT-PCR. Columns, relative mRNA levels for VEGF-C; bars, SE. B, expression of VEGF-A–specific mRNA transcript analyzed by qRT-PCR. Columns, relative mRNA levels for VEGF-C; bars, SE. C, expression of VEGF-C protein levels examined by Western blotting analysis. Columns, arbitrary units (A.U.) representing levels of VEGF-C protein quantitated by densitometry; bars, SE. D, immunohistochemical analysis of VEGF-C expression in Cl66-control cells and Cl66-siVEGF-C cells using anti–VEGF-C antibody. *Significantly different from control.

 
Effect of the VEGF-C gene silencing primary tumor growth. We examined the impact of siRNA-mediated VEGF-C gene silencing on murine mammary tumor growth and metastasis. Stably transfected Cl66-siVEGF-C and Cl66-control cells (1 x 105 cells) were injected orthotopically into BALB/c female mice and tumor growth was monitored twice a week. We did not observe a statistically significant difference in tumor growth between mice injected with Cl66-siVEGFC or Cl66-control cells (Fig. 2A).



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. A, primary tumor growth and VEGF-C expression in vivo. Kinetics of tumor growth in mice injected with Cl66-siVEGFC and Cl66-control cells was examined. Tumor size was measured twice weekly. Points, volume for each group; bars, SE. B, expression levels of VEGF-C in Cl66-siVEGFC tumors and Cl66-control tumors as determined by qRT-PCR. Columns, relative mRNA expression for VEGF-C; bars, SE. *Significantly different from control.

 
We confirmed VEGF-C gene silencing in tumors produced by Cl66-siVEGFC or Cl66-control cells. Specifically, we observed significantly lower expression of VEGF-C mRNA expression in Cl66-siVEGFC tumors compared with Cl66-control tumors (Fig. 2B).

Effect of the VEGF-C gene silencing on tumor lymphangiogenesis. We next examined the effect of VEGF-C gene silencing on lymphangiogenesis in Cl66-siVEGFC and Cl66-control tumors produced by immunohistochemical analysis using an anti–VEGFR-3 antibody. Our data show fewer lymphatics in Cl66-siVEGFC tumors compared with Cl66-control tumors (Fig. 3A, a and b). We further confirmed this observation by qRT-PCR for VEGFR-3 and LYVE-1 using mRNA from tumors produced by Cl66-siVEGFC and Cl66-control cells (Fig. 3B and C). As expected, we observed no difference in neovascularization (by immunohistochemistry using anti-CD31 antibody) between tumors produced by Cl66-siVEGFC and Cl66-control cells (Fig. 3A, c and d). These data suggest that inhibition of VEGF-C in primary tumors by siRNA-mediated gene silencing leads to decreased lymphangiogenesis but not angiogenesis.



View larger version (68K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. A, lymphangiogenesis in mammary tumors expressing different levels of VEGF-C. Cl66-siVEGFC tumor (a) and Cl-66 tumor (b) were immunostained using anti-VEGFR-3 antibody for analysis of lymphangiogenesis. In addition, Cl66-siVEGFC (c) and Cl-66 (d) tumors were immunostained with anti-CD31 antibody for neovascularization analysis. B and C, expression levels of lymphatic markers VEGFR-3 and LYVE-1 in tumors produced by Cl66-siVEGFC and Cl66-control cells as examined by qRT-PCR. Columns, relative mRNA levels for VEGFR-3 or LYVE-1; bars, SE. *Significantly different from control.

 
Effect of the VEGF-C gene silencing on spontaneous metastasis and survival. Overexpression of VEGF-C has been shown to enhance lymph node metastasis in breast cancer. We examined the spontaneous metastatic potential of Cl66-siVEGFC and Cl66-control cells. Mice injected with Cl66-siVEGFC and Cl66-control cells were sacrificed on day 21 and lymph node, lung, liver, and bone marrow were examined for metastasis by immunohistochemistry. We observed a significant inhibition in the incidence of lymph node metastasis in mice injected with Cl66-siVEGFC cells (30%) compared with mice injected with Cl66-control cells (70%; Fig. 4A). In addition, the frequency of pan-cytokeratin–positive metastatic cells in lymph node was significantly lower in mice injected with Cl66-siVEGFC cells compared with mice injected with Cl66-control cells (Fig. 4A).



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Spontaneous lymph node and lung metastasis and survival following mammary fat pad injection of Cl66-siVEGFC and Cl66-control cells. A, lymph node metastasis was examined by pan-cytokeratin staining of tumor cells. Columns, incidence and frequency of pan-cytokeratin–positive cells in the lymph nodes. B, spontaneous lung micrometastasis was determined by H&E staining. The values are incidence, median numbers of micrometastasis, and range of metastatic lung nodules. C, survival rate of mice bearing Cl66-control or Cl66-siVEGFC tumors at different time points. *Significantly different from control.

 
Furthermore, the incidence and number of spontaneous lung metastases in mice injected with Cl66-siVEGFC cells were lower compared with mice injected with Cl66-control cells (Fig. 4B). These data suggest that silencing of VEGF-C gene inhibits regional and distant metastasis in murine mammary tumor cells.

We also examined the difference in the survival of mice injected in the mammary fat pad with Cl66-siVEGFC and Cl66-control cells and observed significantly enhanced survival of mice injected with Cl66-siVEGFC cells compared with Cl66-control cells (Fig. 4C). Taken together, these data show that siRNA-mediated VEGF-C gene silencing in murine mammary tumor cells inhibits lymphangiogenesis and spontaneous lymph node and lung metastasis, leading to increase in survival.

Effect of the VEGF-C gene silencing on experimental lung metastasis and survival. We examined the experimental metastatic potential of Cl66-siVEGFC and Cl66-control cells following i.v. injection into the female BALB/c mice. We sacrificed mice in both groups on day 21 and examined the lungs for metastases. Using this approach, we did not observe significant differences in the incidence and number of lung metastatic nodules in mice injected with Cl66-siVEGFC or Cl66-control tumor cells (Fig. 5A).



View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Experimental lung metastasis and survival. A, mice were injected i.v. with Cl66-control or Cl66-VEGFC-siRNA transfected tumor cells. Mice were killed 3 weeks following tumor injection and lungs were examined for micrometastasis. B, survival rate of mice injected i.v. with Cl66-control or Cl66-siVEGFC cells over time.

 
Mice injected i.v. with Cl66-siVEGF-C cells had significantly enhanced survival compared with mice injected with Cl66-control cells (Fig. 5B). Further, necropsies of the dead mice showed similar numbers of metastatic lung nodules in mice injected with Cl66-siVEGFC cells and Cl66-control cells (data not shown). These data show that siRNA-mediated VEGF-C gene silencing enhanced survival of mice with similar lung tumor burdens.

Inhibition of VEGF-C modulates the tumor-infiltrating immune cell phenotype. BALB/c mice were injected with Cl66-control and Cl66-siVEGFC tumor cells orthotopically. When tumors reached ~1 cm in diameter, mice were sacrificed and tumors were harvested. The frequency of T cell and dendritic cell subsets in tumor-associated leukocytes was determined using cell-specific markers and multicolor flow cytometry. The infiltration of CD4+ T cells in Cl66-control tumors was significantly higher compared with Cl66-siVEGFC tumors (Fig. 6A). In contrast, the infiltration of CD8+ T cells in Cl66-siVEGFC tumors was significantly higher compared with Cl66-control tumors (Fig. 6A and B). In addition, the infiltration of CD11b–CD11c+ cells in Cl66-siVEGFC tumors was significantly higher compared with Cl66-control tumors (Fig. 6C). Next, we examined the proliferation of tumor-associated leukocytes in response to concanavalin A. We observed higher levels of concanavalin A–induced proliferation in tumor-associated leukocytes from Cl66-siVEGF-C tumor-bearing animals compared with tumor-associated leukocytes from Cl66-control tumor-bearing animals (Fig. 6D). These data suggest that inhibition of VEGF-C modulates immune cell infiltration and function, which might be critical in tumor immunity.



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. T cell and dendritic cell phenotype in Cl66-control and Cl66-siVEGFC tumors. The number of CD3+CD4+ (A) and CD+CD8+ (B) T cells and CD11b–CD11c+ (C) dendritic cells in Cl66-control and Cl66-siVEGFC tumors was determined by flow cytometry. The values are number of immune T cells and dendritic cells in per mm3 of tumor. D, tumor-associated leukocytes proliferative response to concanavalin A. Tumor-associated leukocytes from Cl66-siVEGFC and Cl66-control tumors were examined for their proliferative response. Points, cpm from triplicate cultures; bars, SD. This is a representative experiment of three.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In the present study, we showed that siRNA-mediated VEGF-C gene silencing in murine mammary tumors cells inhibited lymphangiogenesis and spontaneous lymph node and lung metastasis, and enhanced survival. For many carcinomas, transport of tumor cells via lymphatics is the pathway of initial dissemination (37), and VEGF-C–mediated enhancement of lymphangiogenesis plays an important role in tumor metastasis (38, 39). To our knowledge, the data described here represent the first evidence that siRNA-mediated VEGF-C gene silencing leads to inhibition of lymphangiogenesis and spontaneous metastasis to lymph nodes and lungs in a metastatic mammary tumor model. Recent reports show that blockade of VEGF-C receptor VEGFR-3 inhibits lymphangiogenesis and metastasis in highly metastatic human lung cancer cell line (40). In this case, He et al. (40) used a receptor antibody fusion protein (VEGFR-3-Ig fusion protein) that traps both VEGF-C and VEGF-D (40). In the present study, we show that specific silencing of VEGF-C gene alone can inhibit tumor lymphangiogenesis in murine mammary tumors.

Clinical and pathologic observations have suggested that initial dissemination of breast cancer is via the lymphatics. Compared to the blood vasculature, little is known about the biology of tumor lymphatics, the regulation of tumor lymphangiogenesis, or mechanisms that determine the interaction of tumor cells with lymphatic vessels (35). Although peritumoral lymphatic vessels contribute to tumor metastasis, opposite views exist as to whether intratumoral lymphatics have any role in tumor metastasis (39). Recent reports using various rodent models provide evidence that tumor VEGF-C–mediated tumor lymphangiogenesis facilitates lymphatic metastasis (41). In addition, using a genetic model, it has been shown that VEGF-C mediates lymphangiogenesis and promotes tumor metastasis (35).

In the present study, we provide evidence that VEGF-C gene silencing inhibited lymphangiogenesis and spontaneous metastasis, and enhanced survival. When overall survival was compared, mice bearing Cl66-siVEGFC tumors lived approximately twice as long as Cl66-control tumor-bearing mice, although the primary mammary tumor size and metastatic burden (in the experimental metastasis studies) were the same for both groups. Our studies suggest that inhibition of tumor VEGF-C production had no direct effect on the regulation of the tumor cell phenotype but might have led to modulation of the tumor microenvironment (such as lymphangiogenesis or recruitment of inflammatory and immune cells). Because VEGF-C might also modulate the immune response, we hypothesize that a decrease in VEGF-C levels might enhance an antitumor immune response, resulting in enhanced survival even if tumor burden is not decreased.

The relationship between immune cell phenotype and VEGF-C expression in cancer remains unclear. A recent report suggests a correlation between tumor expression of VEGF-C with tumor-infiltrating dendritic cell in gastric cancer (42). In this study, there was a direct correlation between VEGF-C expression and poor survival in gastric cancer patients (42). We observed significantly higher number of CD8+ T cells and CD11b–CD11c+ dendritic cells in Cl66-siVEGFC tumors compared with Cl66-control tumors. In addition, we observed significantly enhanced concanavalin A–induced proliferation in tumor-associated leukocytes from Cl66-siVEGFC tumors compared with Cl66-control tumors. The functional role of VEGF-C in the modulation of tumor-specific immune response is not yet clear. Our data suggest that inhibition of VEGF-C expression modulates T cell and dendritic cell phenotype and function, which might affect antitumor immunity. We are currently investigating this possibility by examining the role of VEGF-C in immune cell recruitment and activation and tumor-induced immunosuppression.

In summary, the present study shows that (a) siRNA-mediated VEGF-C gene silencing is an effective tool to inhibit VEGF-C expression in murine mammary tumors cells in vitro and in vivo; (b) inhibition of VEGF-C had no effect on primary tumor growth and experimental lung metastasis; (c) inhibition of VEGF-C inhibited lymphangiogenesis and spontaneous lymph node and lung metastasis, and enhanced survival; and (d) inhibition of VEGF-C modulates dendritic cell and T cell infiltration in tumors. Based on these studies, we suggest that down-regulation of lymphangiogenesis might provide a therapeutic strategy for inhibiting tumor metastasis and for enhancing the survival of patients with breast cancer.


   Acknowledgments
 
Grant support: CA72781 (R.K. Singh) from National Cancer Institute, NIH, and Nebraska Research Initiative Molecular Therapeutics Program (R.K. Singh).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 3/17/05. Revised 7/ 1/05. Accepted 7/25/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Karkkainen MJ, Alitalo K. Lymphatic endothelial regulation, lymphoedema, and lymph node metastasis. Semin Cell Dev Biol 2002;13:9–18.[CrossRef][Medline]
  2. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst 2002;94:417–21.[Free Full Text]
  3. Reis-Filho JS, Schmitt FC. Lymphangiogenesis in tumors: what do we know? Microsc Res Tech 2003;60:171–80.[CrossRef][Medline]
  4. Cunnick GH, Jiang WG, Gomez KF, Mansel RE. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 2002;17:863–70.[Medline]
  5. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276:1423–5.[Abstract/Free Full Text]
  6. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001;7:462–8.[Abstract/Free Full Text]
  7. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001;159:893–903.[Abstract/Free Full Text]
  8. Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003;200:195–206.[CrossRef][Medline]
  9. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315–20.[Abstract/Free Full Text]
  10. Jackson DG. New molecular markers for the study of tumour lymphangiogenesis. Anticancer Res 2001;21:4279–83.[Medline]
  11. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001;22:317–21.[CrossRef][Medline]
  12. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001;276:19420–30.[Abstract/Free Full Text]
  13. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999;144:789–801.[Abstract/Free Full Text]
  14. Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech 2001;55:61–9.[CrossRef][Medline]
  15. Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 2001;21:2351–5.[Medline]
  16. Sinzelle E, Van Huyen JP, Breiteneder-Geleff S, et al. Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. Histopathology 2000;37:93–4.[Medline]
  17. Cursiefen C, Schlotzer-Schrehardt U, Breiteneder-Geleff S, Holbach LM. Orbital lymphangioma with positive immunohistochemistry of lymphatic endothelial markers (vascular endothelial growth factor receptor 3 and podoplanin). Graefes Arch Clin Exp Ophthalmol 2001;239:628–32.[Medline]
  18. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002;21:1505–13.[CrossRef][Medline]
  19. Mouta CC, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001;61:8079–84.[Abstract/Free Full Text]
  20. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 2004;1654:3–12.[Medline]
  21. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15:1751.[Medline]
  22. Marconcini L, Marchio S, Morbidelli L, et al. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A 1999;96:9671–6.[Abstract/Free Full Text]
  23. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967–76.[Abstract/Free Full Text]
  24. Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999;80:309–13.[CrossRef][Medline]
  25. Yonemura Y, Fushida S, Bando E, et al. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 2001;37:918–23.
  26. Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999;5:1823–9.[Abstract/Free Full Text]
  27. Akagi K, Ikeda Y, Miyazaki M, et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000;83:887–91.[CrossRef][Medline]
  28. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000;6:2431–9.[Abstract/Free Full Text]
  29. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003;98:1217–22.[CrossRef][Medline]
  30. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54–61.[CrossRef][Medline]
  31. Koyama Y, Kaneko K, Akazawa K, Kanbayashi C, Kanda T, Hatakeyama K. Vascular endothelial growth factor-C and vascular endothelial growth factor-D messenger RNA expression in breast cancer: association with lymph node metastasis. Clin Breast Cancer 2003;4:354–60.[Medline]
  32. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H. Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol 2004;40:13–20.[CrossRef][Medline]
  33. Pang XH, Tian H, Liu ZY, Li SM, Liu ST, Tian GP. [Significance and expression of vascular endothelial growth factor-C (VEGF-C) in esophageal squamous carcinoma and glioma] [Article in Chinese]. Ai Zheng 2003;22:1166–9.[Medline]
  34. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192–8.[CrossRef][Medline]
  35. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20:672–82.[CrossRef][Medline]
  36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[{Delta}][{Delta}]CT Method. Methods 2001;25:402–8.[CrossRef][Medline]
  37. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004;25:387–95.[CrossRef][Medline]
  38. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573–83.[CrossRef][Medline]
  39. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883–6.[Abstract/Free Full Text]
  40. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002;94:819–25.[Abstract/Free Full Text]
  41. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995;92:3566–70.[Abstract/Free Full Text]
  42. Takahashi A, Kono K, Itakura J, et al. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 2002;62:121–7.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 CirculationHome page
C. Conrad, H. Niess, R. Huss, S. Huber, I. von Luettichau, P. J. Nelson, H. C. Ott, K.-W. Jauch, and C. J. Bruns
Multipotent Mesenchymal Stem Cells Acquire a Lymphendothelial Phenotype and Enhance Lymphatic Regeneration In Vivo
Circulation, January 20, 2009; 119(2): 281 - 289.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Schomber, A. Zumsteg, K. Strittmatter, I. Crnic, H. Antoniadis, A. Littlewood-Evans, J. Wood, and G. Christofori
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis
Mol. Cancer Ther., January 1, 2009; 8(1): 55 - 63.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Miyazaki, N. Okada, K. Ishibashi, K. Ogata, T. Ohsawa, T. Ishiguro, H. Nakada, M. Yokoyama, M. Matsuki, H. Kato, et al.
Clinical Significance of Plasma Level of Vascular Endothelial Growth Factor-C in Patients with Colorectal Cancer
Jpn. J. Clin. Oncol., December 1, 2008; 38(12): 839 - 843.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
J. M. Bock, L. L. Sinclair, N. S. Bedford, R. E. Jackson, J. H. Lee, and D. K. Trask
Modulation of Cellular Invasion by VEGF-C Expression in Squamous Cell Carcinoma of the Head and Neck
Arch Otolaryngol Head Neck Surg, April 1, 2008; 134(4): 355 - 362.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Sundar and T. S. Ganesan
Role of Lymphangiogenesis in Cancer
J. Clin. Oncol., September 20, 2007; 25(27): 4298 - 4307.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. P. Padera, M. Ancukiewicz, T. Hoshida, D. Fukumura, and R. K. Jain
Anti-VEGFR-3 Therapy and Lymph Node Metastasis
Cancer Res., May 15, 2007; 67(10): 5055 - 5055.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Wissmann and M. Detmar
Pathways Targeting Tumor Lymphangiogenesis
Clin. Cancer Res., December 1, 2006; 12(23): 6865 - 6868.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Hoshida, N. Isaka, J. Hagendoorn, E. di Tomaso, Y.-L. Chen, B. Pytowski, D. Fukumura, T. P. Padera, and R. K. Jain
Imaging Steps of Lymphatic Metastasis Reveals That Vascular Endothelial Growth Factor-C Increases Metastasis by Increasing Delivery of Cancer Cells to Lymph Nodes: Therapeutic Implications
Cancer Res., August 15, 2006; 66(16): 8065 - 8075.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Roberts, B. Kloos, M. Cassella, S. Podgrabinska, K. Persaud, Y. Wu, B. Pytowski, and M. Skobe
Inhibition of VEGFR-3 Activation with the Antagonistic Antibody More Potently Suppresses Lymph Node and Distant Metastases than Inactivation of VEGFR-2.
Cancer Res., March 1, 2006; 66(5): 2650 - 2657.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.
Right arrow Articles by Singh, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.
Right arrow Articles by Singh, R. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online